Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Brown Breaks Down How to Choose the Optimal Frontline Approach for CLL

March 3rd 2021

The treatment paradigm for chronic lymphocytic leukemia has expanded beyond continuous treatment with BTK inhibitors with the addition of the time-limited regimen of venetoclax plus obinutuzumab.

Dr. Bociek on Outcomes of Patients With CLL and COVID-19

March 2nd 2021

R. Gregory Bociek, MD, discusses outcomes for patients with chronic lymphocytic leukemia and COVID-19.

Targeted Therapies Dominate the Relapsed/Refractory CLL Paradigm

February 27th 2021

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

Explosion of Data Come From Innovative Combos in CLL

February 26th 2021

The progress made with novel combination regimens coupled with their game-changing data in both frontline and relapsed/refractory chronic lymphocytic leukemia is unprecedented.

Cirmtuzumab/Ibrutinib Shows Encouraging Clinical Activity, Safety in MCL and CLL

February 26th 2021

Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Ianalumab/Ibrutinib Combo Shows Promising Activity in CLL

February 26th 2021

Kerry A, Rogers, MD, discusses the rationale behind the phase 1b study of VAY736 combined with ibrutinib in patients with chronic lymphocytic leukemia and the next steps for this research.

Dr. Bociek on the Evolving Role of Prognostic Factors in CLL

February 24th 2021

R. Gregory Bociek, MD, discusses the evolving role of prognostic factors in chronic lymphocytic leukemia.

Time-Limited Therapy Takes Center Stage in Frontline and Relapsed/Refractory CLL

February 24th 2021

Fixed-duration treatment that leads to deep treatment-free remissions has become the prioritized strategy for patients with chronic lymphocytic leukemia, made possible by agents such as venetoclax, umbralisib, and lisocabtagene maraleucel.

Novel Treatment Combinations in Chronic Lymphocytic Leukemia

February 24th 2021

Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.

The Future of Chronic Lymphocytic Leukemia Treatment

February 24th 2021

Dr Ghia discusses emerging treatment strategies, including some promising clinical trials in chronic lymphocytic leukemia.

Treatment Sequencing in Chronic Lymphocytic Leukemia

February 24th 2021

Experts provide an in-depth look at their approach in sequencing treatment in chronic lymphocytic leukemia.

Dr. Al-Sawaf on Efforts Examining Venetoclax/Obinutuzumab in CLL

February 24th 2021

Othman Al-Sawaf, MD, discusses research efforts that are evaluating the use of venetoclax and obinutuzumab in patients with chronic lymphocytic leukemia.

Final GENUINE Data Support Addition of Ublituximab to BTK Inhibitors in Relapsed/Refractory, High-Risk CLL

February 23rd 2021

Feburary 23, 2021 — The addition of the anti-CD20 monoclonal antibody ublituximab to ibrutinib led to a statistically higher overall response rate over ibrutinib alone with acceptable safety in patients with relapsed/refractory, high-risk, chronic lymphocytic leukemia.

Dr. Bociek on the Evolving Role of Chemoimmunotherapy in CLL

February 22nd 2021

R. Gregory Bociek, MD, discusses the evolving role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Shadman on the Potential for CAR T-Cell Therapy in High-Risk CLL

February 20th 2021

Mazyar Shadman, MD, discusses the potential for CAR T-cell therapy in patients with high-risk chronic lymphocytic leukemia.

Dr. Shadman on the Potential Utility of LOXO-305 in CLL

February 18th 2021

Mazyar Shadman, MD, discusses the potential utility of LOXO-305 in chronic lymphocytic leukemia.

Treatment Options in Relapsed/Refractory Chronic Lymphocytic Leukemia

February 17th 2021

Experts discuss second-line treatment options in relapsed/refractory chronic lymphocytic leukemia, including a discussion on the MURANO trial.

Chronic Lymphocytic Leukemia Treatment Considerations

February 17th 2021

Dr Brown and Dr Stilgenbauer provide advice for community-based oncologists treating chronic lymphocytic leukemia.

Targeted Therapies Reign in the Frontline Treatment of CLL

February 16th 2021

Jacqueline Claudia Barrientos, MD, MS, explaines how she navigates among the options available in the frontline setting for patients with CLL and highlighted ongoing research efforts of interest.

Dr. Mead on the Clinical Significance of the MURANO Trial in CLL

February 15th 2021

Monica D. Mead, MD, discusses the clinical significance of the phase 3 MURANO trial in chronic lymphocytic leukemia.